8-K - Bicara Therapeutics Inc. (0002023658) (Filer)

424B5 - Bicara Therapeutics Inc. (0002023658) (Filer)

FWP - Bicara Therapeutics Inc. (0002023658) (Subject)

424B5 - Bicara Therapeutics Inc. (0002023658) (Filer)

8-K - Bicara Therapeutics Inc. (0002023658) (Filer)

SCHEDULE 13G/A - Bicara Therapeutics Inc. (0002023658) (Subject)

SCHEDULE 13G - Bicara Therapeutics Inc. (0002023658) (Subject)

SCHEDULE 13G - Bicara Therapeutics Inc. (0002023658) (Subject)

SCHEDULE 13G/A - Bicara Therapeutics Inc. (0002023658) (Subject)

8-K - Bicara Therapeutics Inc. (0002023658) (Filer)

4 - Bicara Therapeutics Inc. (0002023658) (Issuer)

4 - Bicara Therapeutics Inc. (0002023658) (Issuer)

4 - Bicara Therapeutics Inc. (0002023658) (Issuer)

4 - Bicara Therapeutics Inc. (0002023658) (Issuer)

4 - Bicara Therapeutics Inc. (0002023658) (Issuer)

4 - Bicara Therapeutics Inc. (0002023658) (Issuer)

4 - Bicara Therapeutics Inc. (0002023658) (Issuer)

4 - Bicara Therapeutics Inc. (0002023658) (Issuer)

4 - Bicara Therapeutics Inc. (0002023658) (Issuer)

4 - Bicara Therapeutics Inc. (0002023658) (Issuer)

4 - Bicara Therapeutics Inc. (0002023658) (Issuer)

Citizens JMP initiated coverage of Bicara Therapeutics with a rating of Mkt Perform and set a new price target of $31.00

BTIG Research initiated coverage of Bicara Therapeutics with a rating of Buy and set a new price target of $28.00

Mizuho initiated coverage of Bicara Therapeutics with a rating of Neutral and set a new price target of $18.00

Piper Sandler initiated coverage of Bicara Therapeutics with a rating of Overweight and set a new price target of $36.00

Wells Fargo upgraded Bicara Therapeutics from Underweight to Equal Weight and set a new price target of $8.00

Wells Fargo initiated coverage of Bicara Therapeutics with a rating of Underweight and set a new price target of $8.00

Wedbush initiated coverage of Bicara Therapeutics with a rating of Outperform and set a new price target of $31.00

H.C. Wainwright initiated coverage of Bicara Therapeutics with a rating of Buy and set a new price target of $42.00

Rodman & Renshaw initiated coverage of Bicara Therapeutics with a rating of Buy and set a new price target of $48.00

Cantor Fitzgerald initiated coverage of Bicara Therapeutics with a rating of Overweight

BOSTON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced the closing of its underwritten public offering of 8,581,250 shares of its common stock, and to certain investors that so choose, pre-funded warrants to purchase 2,200,000 shares of its common stock at an exercise price of $0.0001 per share. The shares of common stock sold include 1,406,250 shares pursuant to the option granted by Bicara to the underwriters, which option was exercised in full. The public offering price of each share of common stock was $16.00 an

BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced the pricing of an underwritten public offering of 7,175,000 shares of its common stock at a public offering price of $16.00 per share and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase 2,200,000 shares of common stock at a public offering price of $15.9999 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.0001 per share exercise price for each pre-funded wa

BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that it has commenced an underwritten public offering of $150 million of shares of its common stock. Bicara intends to grant the underwriters a 30-day option to purchase up to an additional $22,500,000 of shares of common stock offered in the public offering, at the public offering price, less underwriting discounts and commissions. All of the shares of common stock to be sold in the proposed offering will be sold by Bicara. Morgan Stanley, TD Cowen, BofA Securi

BOSTON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that company leadership will participate in multiple upcoming investor conferences. Ryan Cohlhepp, Pharm.D., President and Chief Operating Officer at Bicara will take part in fireside chats at: TD Cowen 46th Annual Health Care Conference Date and Time: Monday, March 2, 1:10-1:40 p.m. ET in Boston Barclays 28th Annual Global Healthcare Conference Date and Time: Tuesday, March 10, 11:30-11:55 a.m. ET in Miami Bicara management will also attend the 2026 Jeffe

Phase 1b expansion cohort data evaluating 2000mg of ficerafusp alfa every other week in combination with pembrolizumab in 1L HPV-negative R/M HNSCC patients demonstrate rapid, deep and durable responses with generally well-tolerated safety profile  Company plans to develop a loading and every-three-week maintenance regimen for ficerafusp alfa, pending regulatory alignment Company to host conference call and webcast on Friday, February 20, 2026 at 8:30 a.m. ET BOSTON, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today presented

BOSTON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced it awarded inducement grants on February 2, 2026 to two new employees under Bicara's 2026 Inducement Plan as a material inducement to employment. The employees received, in the aggregate, non-qualified stock options to purchase 158,900 shares of Bicara's common stock, par value $0.0001 per share, with an exercise price of $16.76 per share, equal to the closing price of Bicara's common stock as reported by Nasdaq on February 2, 2026. One-fourth of the options ve

Selected 1500 mg of ficerafusp alfa as the optimal dose for the treatment of 1L HPV-negative R/M HNSCC in Phase 3 FORTIFI-HN01 pivotal study Expects to achieve substantial enrollment in FORTIFI-HN01 in 2026 to enable interim analysis in mid-2027 Anticipates multiple expansion cohort data readouts in 2026 to further characterize ficerafusp alfa's profile in HPV-negative HNSCC and support potential expansion into other solid tumor types, including colorectal cancer Claire Mazumdar, PhD, MBA, Chief Executive Officer, to present at the J.P. Morgan 2026 Healthcare Conference on Monday, January 12 at 11:15 a.m. PT (2:15 p.m. ET) BOSTON, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics

BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that Claire Mazumdar, PhD, MBA, Chief Executive Officer, will present at the J.P. Morgan 2026 Healthcare Conference on Monday, January 12, 2026 at 11:15 a.m. PT. A live webcast of the presentation will be accessible through the Investor Relations section of Bicara's website under Events and Presentations. A replay of the webcast will be archived and available following the event. About Bicara Therapeutics Bicara Therapeutics is a clinical-stage biopharmaceutic

Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety profile comparable to 1500mg QW dose, further derisking pivotal FORTIFI-HN01 study interim analysis Totality of data demonstrates that greater TGF-β inhibition, observed at 1500mg of ficerafusp alfa, drives deeper tumor responses that translate to more durable outcomes for patients Pivotal FORTIFI-HN01 optimal dose declaration expected in first quarter 2026 Company to host conference call and webcast today at 9:00 a.m. ET BOSTON, Dec. 06, 2025 (GLOBE NEWSWIRE) --  Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing t

Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates overall response rate and safety profile consistent with the 1500mg QW dose Data inform and advance progress toward dose selection for ongoing pivotal FORTIFI-HN01 clinical trial of ficerafusp alfa in combination with pembrolizumab in 1L HPV-negative R/M HNSCC Company to host conference call and webcast on Saturday, December 6, 2025 at 9:00 a.m. ET BOSTON, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced the publication of an abstract with ear

Phase 1b expansion cohort data evaluating 2000mg of ficerafusp alfa every other week in combination with pembrolizumab in 1L HPV-negative R/M HNSCC patients demonstrate rapid, deep and durable responses with generally well-tolerated safety profile  Company plans to develop a loading and every-three-week maintenance regimen for ficerafusp alfa, pending regulatory alignment Company to host conference call and webcast on Friday, February 20, 2026 at 8:30 a.m. ET BOSTON, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today presented

Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety profile comparable to 1500mg QW dose, further derisking pivotal FORTIFI-HN01 study interim analysis Totality of data demonstrates that greater TGF-β inhibition, observed at 1500mg of ficerafusp alfa, drives deeper tumor responses that translate to more durable outcomes for patients Pivotal FORTIFI-HN01 optimal dose declaration expected in first quarter 2026 Company to host conference call and webcast today at 9:00 a.m. ET BOSTON, Dec. 06, 2025 (GLOBE NEWSWIRE) --  Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing t

Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates overall response rate and safety profile consistent with the 1500mg QW dose Data inform and advance progress toward dose selection for ongoing pivotal FORTIFI-HN01 clinical trial of ficerafusp alfa in combination with pembrolizumab in 1L HPV-negative R/M HNSCC Company to host conference call and webcast on Saturday, December 6, 2025 at 9:00 a.m. ET BOSTON, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced the publication of an abstract with ear

Median DOR of 21.7 months with 80% of responders achieving a deep response (≥80% tumor shrinkage) Depth and durability translating to prolonged OS with median OS of 21.3 months and 2-year OS of 46% in HPV-negative HNSCC Conference call and webcast today at 3:00 p.m. CT / 4:00 p.m. ET BOSTON, June 01, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today presented updated data from the company's Phase 1/1b clinical trial of ficerafusp alfa in combination with pembrolizumab in patients with first line (1L) recurrent/metastatic (R/M) head an

BOSTON, May 22, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced the publication of an abstract with updated interim data from the company's Phase 1/1b clinical trial of ficerafusp alfa in combination with pembrolizumab in patients with first line (1L) recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) on the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting website. The company will host a conference call on Sunday, June 1, 2025 at 3:00 p.m. CT / 4:00 p.m. ET to present the fulsome dataset

SC 13G - Bicara Therapeutics Inc. (0002023658) (Subject)

SC 13G - Bicara Therapeutics Inc. (0002023658) (Subject)

SC 13D - Bicara Therapeutics Inc. (0002023658) (Subject)

HOUSTON, July 31, 2025 /PRNewswire/ -- The Rice Biotech Launch Pad, a Houston-based accelerator focused on expediting the translation of Rice University's health and medical technology discoveries into cures, announced today the appointment of Carolyn Ng to its external advisory board. A current business unit partner at TPG Life Sciences Innovations, Ng brings expertise in biotech and company building with a track record of guiding early to midstage companies across a wide range of therapeutic areas. "Carolyn's deep understanding of translational science, combined with her passion for fostering high-impact ventures, makes her an ideal addition to the board," said Omid Veiseh, professor of b

CAMBRIDGE, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced the appointment of Claire Mazumdar, Ph.D., to the Company's Board of Directors, effective June 9, 2025. "It is a privilege to welcome Claire to our Board, where she will draw from her strategic and operational experience in clinical-stage oncology to offer guidance as we prepare to initiate our Phase 3 ReDiscover-2 trial in breast cancer soon," said Sanjiv Patel, M.D., President and Chief Executive Officer of Relay Therapeutics.